Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyRuxolitinib
Identification
- Name
- Ruxolitinib
- Accession Number
- DB08877
- Type
- Small Molecule
- Groups
- Approved
- Description
Ruxolitinib is a janus-associated kinase inhibitor indicated to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis. FDA approved on November 16, 2011.
- Structure
Structure for DB08877 (Ruxolitinib)
- Synonyms
- INCB424
- External IDs
- INC-424 / INC424 / INCB 18424 / INCB-018424 / INCB-18424 / INCB018424
- Product Ingredients
Ingredient UNII CAS InChI Key Ruxolitinib Phosphate 436LRU32H5 1092939-17-7 JFMWPOCYMYGEDM-XFULWGLBSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Jakafi Tablet 15 mg/1 Oral Incyte Corporation 2011-11-16 Not applicable US 
Jakafi Tablet 25 mg/1 Oral Incyte Corporation 2011-11-16 Not applicable US Jakafi Tablet 10 mg/1 Oral Incyte Corporation 2011-11-16 Not applicable US Jakafi Tablet 20 mg/1 Oral Incyte Corporation 2011-11-16 Not applicable US Jakafi Tablet 5 mg/1 Oral Incyte Corporation 2011-11-16 Not applicable US Jakavi Tablet 10 mg Oral Novartis Europharm Limited 2012-08-23 Not applicable EU 
Jakavi Tablet 5 mg Oral Novartis 2012-07-19 Not applicable Canada 
Jakavi Tablet 15 mg Oral Novartis Europharm Limited 2012-08-23 Not applicable EU Jakavi Tablet 5 mg Oral Novartis Europharm Limited 2012-08-23 Not applicable EU Jakavi Tablet 10 mg Oral Novartis Europharm Limited 2012-08-23 Not applicable EU - Categories
- UNII
- 82S8X8XX8H
- CAS number
- 941678-49-5
- Weight
- Average: 306.365
Monoisotopic: 306.159294606 - Chemical Formula
- C17H18N6
- InChI Key
- HFNKQEVNSGCOJV-OAHLLOKOSA-N
- InChI
- InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
- IUPAC Name
- (3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile
- SMILES
- N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
Pharmacology
- Indication
Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).
- Associated Conditions
- Pharmacodynamics
The mean half-maximal inhibitory concentration (IC50) for JAK 1 and JAK 2 are 2.8 nmol/L and 3.3 nmol/L respectively. After administration of ruxolitinib, a decrease in levels of phosphorylated STAT (marker for JAK activity) in a dose-dependent manner can be observed. Pharmacodynamic resistance has not been observed.
- Mechanism of action
Ruxolitinib is a kinase inhibitor that is selective for the Janus Associated Kinases (JAK) 1 and 2. These kinases are responsible for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. The signalling process involves signal transducers and transcription activators (STAT) which modulate gene expression. Patients with myelofibrosis have abnormal JAK1 and JAK2 activity thus ruxolitinib works to regulate this.
Target Actions Organism ATyrosine-protein kinase JAK1 inhibitorHuman ATyrosine-protein kinase JAK2 inhibitorHuman - Absorption
Absorption is rapid and is not affected by food. Cmax, 15 mg, healthy subject = 649 nmol/L; Tmax, 15 mg, healthy subject = 1.5 hours; Ruxolitinib does not accumulate significantly.
- Volume of distribution
Terminal phase volume of distribution, 15 mg, healthy subject = 76.6 L.
- Protein binding
97% protein bound, primarily to albumin.
- Metabolism
Ruxolitinib is metabolized by CYP3A4. Less potent active metabolites forms as a result.
- Route of elimination
Eliminated via urine (74%, <1% as unchanged drug) and feces (22%, <1% as unchanged drug).
- Half life
Mean elimination half-life, 15 mg, healthy subject = 2.8 hours.
- Clearance
15 mg, healthy subject = 18.7 L/h.
- Toxicity
Thrombocytopenia was the dose-limiting toxicity.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Acebutolol Ruxolitinib may increase the bradycardic activities of Acebutolol. Approved, Investigational Acetyl sulfisoxazole The metabolism of Ruxolitinib can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Ruxolitinib. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Ruxolitinib. Experimental Amiodarone The serum concentration of Ruxolitinib can be increased when it is combined with Amiodarone. Approved, Investigational Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Ruxolitinib. Approved, Investigational, Withdrawn Anthrax immune globulin human The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Anthrax immune globulin human. Approved Apalutamide The serum concentration of Ruxolitinib can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The serum concentration of Ruxolitinib can be increased when it is combined with Aprepitant. Approved, Investigational Atazanavir The serum concentration of Ruxolitinib can be increased when it is combined with Atazanavir. Approved, Investigational Atenolol Ruxolitinib may increase the bradycardic activities of Atenolol. Approved Atomoxetine The metabolism of Ruxolitinib can be decreased when combined with Atomoxetine. Approved Bacillus calmette-guerin substrain connaught live antigen The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Bacillus calmette-guerin substrain tice live antigen The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Bacillus calmette-guerin substrain tice live antigen. Approved BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ruxolitinib. Investigational Bendroflumethiazide Ruxolitinib may increase the bradycardic activities of Bendroflumethiazide. Approved Beractant Ruxolitinib may increase the bradycardic activities of Beractant. Approved Betaxolol Ruxolitinib may increase the bradycardic activities of Betaxolol. Approved, Investigational Bevacizumab Bevacizumab may increase the cardiotoxic activities of Ruxolitinib. Approved, Investigational Bisoprolol Ruxolitinib may increase the bradycardic activities of Bisoprolol. Approved Boceprevir The serum concentration of Ruxolitinib can be increased when it is combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Ruxolitinib can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Ruxolitinib can be decreased when it is combined with Bosentan. Approved, Investigational Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ruxolitinib. Approved Calfactant Ruxolitinib may increase the bradycardic activities of Calfactant. Approved Carbamazepine The metabolism of Ruxolitinib can be increased when combined with Carbamazepine. Approved, Investigational Carteolol Ruxolitinib may increase the bradycardic activities of Carteolol. Approved Carvedilol Ruxolitinib may increase the bradycardic activities of Carvedilol. Approved, Investigational Ceritinib The serum concentration of Ruxolitinib can be increased when it is combined with Ceritinib. Approved Clarithromycin The serum concentration of Ruxolitinib can be increased when it is combined with Clarithromycin. Approved Clemastine The metabolism of Ruxolitinib can be decreased when combined with Clemastine. Approved, Investigational Clonidine Ruxolitinib may increase the bradycardic activities of Clonidine. Approved Clostridium tetani toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated). Approved Clotrimazole The metabolism of Ruxolitinib can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Clozapine. Approved Cobicistat The serum concentration of Ruxolitinib can be increased when it is combined with Cobicistat. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Ruxolitinib. Approved, Investigational Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated). Approved Crizotinib Ruxolitinib may increase the bradycardic activities of Crizotinib. Approved Curcumin The serum concentration of Ruxolitinib can be increased when it is combined with Curcumin. Approved, Investigational Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Ruxolitinib. Approved, Investigational Cyclosporine The metabolism of Ruxolitinib can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cymarin Cymarin may decrease the cardiotoxic activities of Ruxolitinib. Experimental Dabrafenib The serum concentration of Ruxolitinib can be decreased when it is combined with Dabrafenib. Approved, Investigational Darunavir The serum concentration of Ruxolitinib can be increased when it is combined with Darunavir. Approved Dasatinib The serum concentration of Ruxolitinib can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Ruxolitinib can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Ruxolitinib can be decreased when combined with Delavirdine. Approved Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Ruxolitinib. Approved Deslanoside Deslanoside may decrease the cardiotoxic activities of Ruxolitinib. Approved Dexmedetomidine Ruxolitinib may increase the bradycardic activities of Dexmedetomidine. Approved, Vet Approved Digitoxin Digitoxin may decrease the cardiotoxic activities of Ruxolitinib. Approved, Investigational Digoxin Ruxolitinib may increase the bradycardic activities of Digoxin. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ruxolitinib. Approved Dihydroergotamine The metabolism of Ruxolitinib can be decreased when combined with Dihydroergotamine. Approved, Investigational Diltiazem Ruxolitinib may increase the bradycardic activities of Diltiazem. Approved, Investigational Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Ruxolitinib. Approved, Investigational Donepezil Ruxolitinib may increase the bradycardic activities of Donepezil. Approved Doxycycline The metabolism of Ruxolitinib can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone Ruxolitinib may increase the bradycardic activities of Dronedarone. Approved Enzalutamide The serum concentration of Ruxolitinib can be decreased when it is combined with Enzalutamide. Approved Erythromycin The metabolism of Ruxolitinib can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Esmolol Ruxolitinib may increase the bradycardic activities of Esmolol. Approved Fingolimod Ruxolitinib may increase the immunosuppressive activities of Fingolimod. Approved, Investigational Fluconazole The serum concentration of Ruxolitinib can be increased when it is combined with Fluconazole. Approved, Investigational Fluvoxamine The metabolism of Ruxolitinib can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Ruxolitinib can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Ruxolitinib can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The metabolism of Ruxolitinib can be increased when combined with Fosphenytoin. Approved, Investigational Fusidic Acid The serum concentration of Ruxolitinib can be increased when it is combined with Fusidic Acid. Approved, Investigational G17DT The risk or severity of adverse effects can be increased when Ruxolitinib is combined with G17DT. Investigational Galantamine Ruxolitinib may increase the bradycardic activities of Galantamine. Approved GI-5005 The risk or severity of adverse effects can be increased when Ruxolitinib is combined with GI-5005. Investigational Gitoformate Gitoformate may decrease the cardiotoxic activities of Ruxolitinib. Experimental Guanfacine Ruxolitinib may increase the bradycardic activities of Guanfacine. Approved, Investigational Hepatitis A Vaccine The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Hepatitis A Vaccine. Approved Hepatitis B Vaccine (Recombinant) The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Hepatitis B Vaccine (Recombinant). Approved, Withdrawn Human rabies virus immune globulin The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Human rabies virus immune globulin. Approved Idelalisib The serum concentration of Ruxolitinib can be increased when it is combined with Idelalisib. Approved Imatinib The metabolism of Ruxolitinib can be decreased when combined with Imatinib. Approved Indinavir The serum concentration of Ruxolitinib can be increased when it is combined with Indinavir. Approved INGN 201 The risk or severity of adverse effects can be increased when Ruxolitinib is combined with INGN 201. Investigational INGN 225 The risk or severity of adverse effects can be increased when Ruxolitinib is combined with INGN 225. Investigational Isavuconazole The serum concentration of Ruxolitinib can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Ruxolitinib can be decreased when combined with Isavuconazonium. Approved, Investigational Isradipine The metabolism of Ruxolitinib can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The serum concentration of Ruxolitinib can be increased when it is combined with Itraconazole. Approved, Investigational Ivabradine Ruxolitinib may increase the bradycardic activities of Ivabradine. Approved Ivacaftor The serum concentration of Ruxolitinib can be increased when it is combined with Ivacaftor. Approved Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated). Approved Ketoconazole The serum concentration of Ruxolitinib can be increased when it is combined with Ketoconazole. Approved, Investigational Labetalol Ruxolitinib may increase the bradycardic activities of Labetalol. Approved Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Ruxolitinib. Experimental Lanreotide Ruxolitinib may increase the bradycardic activities of Lanreotide. Approved Leflunomide The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Leflunomide. Approved, Investigational Levobunolol Ruxolitinib may increase the bradycardic activities of Levobunolol. Approved Lipegfilgrastim Ruxolitinib may increase the myelosuppressive activities of Lipegfilgrastim. Approved, Investigational Lopinavir The serum concentration of Ruxolitinib can be increased when it is combined with Lopinavir. Approved Lorpiprazole The serum concentration of Ruxolitinib can be increased when it is combined with Lorpiprazole. Approved Lovastatin The metabolism of Ruxolitinib can be decreased when combined with Lovastatin. Approved, Investigational Lucinactant Ruxolitinib may increase the bradycardic activities of Lucinactant. Approved, Investigational Luliconazole The serum concentration of Ruxolitinib can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Ruxolitinib can be increased when combined with Lumacaftor. Approved Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Ruxolitinib. Approved, Investigational, Withdrawn Methyldopa Ruxolitinib may increase the bradycardic activities of Methyldopa. Approved Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Ruxolitinib. Experimental Metipranolol Ruxolitinib may increase the bradycardic activities of Metipranolol. Approved Metoprolol Ruxolitinib may increase the bradycardic activities of Metoprolol. Approved, Investigational Mifepristone The serum concentration of Ruxolitinib can be increased when it is combined with Mifepristone. Approved, Investigational Mitotane The serum concentration of Ruxolitinib can be decreased when it is combined with Mitotane. Approved Nadolol Ruxolitinib may increase the bradycardic activities of Nadolol. Approved Natalizumab The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Natalizumab. Approved, Investigational Nebivolol Ruxolitinib may increase the bradycardic activities of Nebivolol. Approved, Investigational Nefazodone The serum concentration of Ruxolitinib can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Ruxolitinib can be increased when it is combined with Nelfinavir. Approved Netupitant The serum concentration of Ruxolitinib can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Ruxolitinib can be increased when combined with Nevirapine. Approved Nilotinib The metabolism of Ruxolitinib can be decreased when combined with Nilotinib. Approved, Investigational Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Ruxolitinib. Approved, Investigational Octreotide Ruxolitinib may increase the bradycardic activities of Octreotide. Approved, Investigational Olaparib The metabolism of Ruxolitinib can be decreased when combined with Olaparib. Approved Oleandrin Oleandrin may decrease the cardiotoxic activities of Ruxolitinib. Experimental, Investigational Osimertinib The serum concentration of Ruxolitinib can be increased when it is combined with Osimertinib. Approved Ouabain Ouabain may decrease the cardiotoxic activities of Ruxolitinib. Approved Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ruxolitinib. Approved, Vet Approved Palbociclib The serum concentration of Ruxolitinib can be increased when it is combined with Palbociclib. Approved, Investigational Pasireotide Ruxolitinib may increase the bradycardic activities of Pasireotide. Approved Penbutolol Ruxolitinib may increase the bradycardic activities of Penbutolol. Approved, Investigational Pentobarbital The metabolism of Ruxolitinib can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Peruvoside Peruvoside may decrease the cardiotoxic activities of Ruxolitinib. Experimental Phenobarbital The metabolism of Ruxolitinib can be increased when combined with Phenobarbital. Approved, Investigational Phenytoin The metabolism of Ruxolitinib can be increased when combined with Phenytoin. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ruxolitinib. Approved, Investigational Pindolol Ruxolitinib may increase the bradycardic activities of Pindolol. Approved, Investigational Pitolisant The serum concentration of Ruxolitinib can be decreased when it is combined with Pitolisant. Approved, Investigational Poractant alfa Ruxolitinib may increase the bradycardic activities of Poractant alfa. Approved Posaconazole The serum concentration of Ruxolitinib can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Primidone The metabolism of Ruxolitinib can be increased when combined with Primidone. Approved, Vet Approved Propafenone Ruxolitinib may increase the bradycardic activities of Propafenone. Approved Propranolol Ruxolitinib may increase the bradycardic activities of Propranolol. Approved, Investigational Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Ruxolitinib. Experimental Rabies virus inactivated antigen, A The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Rabies virus inactivated antigen, A. Approved, Investigational Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ruxolitinib. Approved, Investigational Ranolazine The metabolism of Ruxolitinib can be decreased when combined with Ranolazine. Approved, Investigational Rifabutin The metabolism of Ruxolitinib can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Ruxolitinib can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Ruxolitinib can be increased when combined with Rifapentine. Approved, Investigational Rindopepimut The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Rindopepimut. Investigational Rivastigmine Ruxolitinib may increase the bradycardic activities of Rivastigmine. Approved, Investigational Roflumilast Roflumilast may increase the immunosuppressive activities of Ruxolitinib. Approved Rotavirus Vaccine The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Rotavirus Vaccine. Approved Rubella virus vaccine The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Rubella virus vaccine. Approved, Investigational Rucaparib The metabolism of Ruxolitinib can be decreased when combined with Rucaparib. Approved, Investigational Salmonella typhi ty2 vi polysaccharide antigen The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Salmonella typhi ty2 vi polysaccharide antigen. Approved Salmonella typhi ty21a live antigen The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Salmonella typhi ty21a live antigen. Approved Saquinavir The serum concentration of Ruxolitinib can be increased when it is combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Ruxolitinib can be decreased when used in combination with Sarilumab. Approved, Investigational Sildenafil The metabolism of Ruxolitinib can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Ruxolitinib can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Ruxolitinib can be increased when it is combined with Simeprevir. Approved Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ruxolitinib. Approved, Investigational Sotalol Ruxolitinib may increase the bradycardic activities of Sotalol. Approved SRP 299 The risk or severity of adverse effects can be increased when Ruxolitinib is combined with SRP 299. Investigational St. John's Wort The serum concentration of Ruxolitinib can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Ruxolitinib can be increased when it is combined with Stiripentol. Approved Sufentanil Ruxolitinib may increase the bradycardic activities of Sufentanil. Approved, Investigational Sulfisoxazole The metabolism of Ruxolitinib can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Tacrolimus Tacrolimus may increase the immunosuppressive activities of Ruxolitinib. Approved, Investigational Tecemotide The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Tecemotide. Investigational Telaprevir The serum concentration of Ruxolitinib can be increased when it is combined with Telaprevir. Approved, Withdrawn Telithromycin The serum concentration of Ruxolitinib can be increased when it is combined with Telithromycin. Approved TG4010 The risk or severity of adverse effects can be increased when Ruxolitinib is combined with TG4010. Investigational Ticlopidine The metabolism of Ruxolitinib can be decreased when combined with Ticlopidine. Approved Timolol Ruxolitinib may increase the bradycardic activities of Timolol. Approved Tizanidine Ruxolitinib may increase the bradycardic activities of Tizanidine. Approved, Investigational Tocilizumab The serum concentration of Ruxolitinib can be decreased when it is combined with Tocilizumab. Approved Tofacitinib Ruxolitinib may increase the immunosuppressive activities of Tofacitinib. Approved, Investigational Trastuzumab Trastuzumab may increase the cardiotoxic activities of Ruxolitinib. Approved, Investigational Typhoid Vaccine The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Typhoid Vaccine. Approved Varicella Zoster Vaccine (Live/Attenuated) The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Varicella Zoster Vaccine (Live/Attenuated). Approved Vemurafenib The serum concentration of Ruxolitinib can be decreased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Ruxolitinib can be decreased when combined with Venlafaxine. Approved Verapamil Ruxolitinib may increase the bradycardic activities of Verapamil. Approved Voriconazole The serum concentration of Ruxolitinib can be increased when it is combined with Voriconazole. Approved, Investigational Yellow Fever Vaccine The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Yellow Fever Vaccine. Approved, Investigational Ziprasidone The metabolism of Ruxolitinib can be decreased when combined with Ziprasidone. Approved - Food Interactions
- Take without regards to meals
References
- General References
- Cervantes F, Martinez-Trillos A: Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013 May;14(7):873-84. doi: 10.1517/14656566.2013.783019. Epub 2013 Mar 21. [PubMed:23514013]
- Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. [PubMed:23061804]
- External Links
- KEGG Drug
- D09959
- PubChem Compound
- 25126798
- PubChem Substance
- 175427129
- ChemSpider
- 25027389
- BindingDB
- 50355501
- ChEBI
- 66919
- ChEMBL
- CHEMBL1789941
- PharmGKB
- PA166123386
- HET
- RXT
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Ruxolitinib
- ATC Codes
- L01XE18 — Ruxolitinib
- AHFS Codes
- 10:00.00 — Antineoplastic Agents
- PDB Entries
- 4u5j
- FDA label
- Download (399 KB)
- MSDS
- Download (210 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Tablet Oral 10 mg/1 Tablet Oral 15 mg/1 Tablet Oral 20 mg/1 Tablet Oral 25 mg/1 Tablet Oral 5 mg/1 Tablet Oral 10 mg Tablet Oral 15 mg Tablet Oral 20 mg Tablet Oral 5 mg - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US7598257 No 2007-12-24 2027-12-24 US US8822481 No 2008-06-12 2028-06-12 US US8829013 No 2008-06-12 2028-06-12 US US9079912 No 2006-12-12 2026-12-12 US US8415362 No 2007-12-24 2027-12-24 US US8722693 No 2008-06-12 2028-06-12 US US9662335 No 2006-12-12 2026-12-12 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Soluble in aqueous buffers across a pH of 1-8 FDA label. - Predicted Properties
Property Value Source Water Solubility 0.116 mg/mL ALOGPS logP 2.94 ALOGPS logP 2.48 ChemAxon logS -3.4 ALOGPS pKa (Strongest Acidic) 13.89 ChemAxon pKa (Strongest Basic) 5.51 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 83.18 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 98.01 m3·mol-1 ChemAxon Polarizability 33.04 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9673 Caco-2 permeable - 0.5198 P-glycoprotein substrate Non-substrate 0.7838 P-glycoprotein inhibitor I Non-inhibitor 0.8228 P-glycoprotein inhibitor II Inhibitor 0.7092 Renal organic cation transporter Non-inhibitor 0.5098 CYP450 2C9 substrate Non-substrate 0.8394 CYP450 2D6 substrate Non-substrate 0.8075 CYP450 3A4 substrate Non-substrate 0.6535 CYP450 1A2 substrate Inhibitor 0.6426 CYP450 2C9 inhibitor Non-inhibitor 0.7731 CYP450 2D6 inhibitor Non-inhibitor 0.9208 CYP450 2C19 inhibitor Non-inhibitor 0.6689 CYP450 3A4 inhibitor Non-inhibitor 0.6655 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5753 Ames test AMES toxic 0.5681 Carcinogenicity Non-carcinogens 0.9308 Biodegradation Not ready biodegradable 0.9917 Rat acute toxicity 2.5724 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.633 hERG inhibition (predictor II) Non-inhibitor 0.8772
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as pyrrolo[2,3-d]pyrimidines. These are aromatic heteropolycyclic compounds containing a pyrrolo[2,3-d]pyrimidine ring system, which is an pyrrolopyrimidine isomers having the 3 ring nitrogen atoms at the 1-, 5-, and 7-positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyrrolopyrimidines
- Sub Class
- Pyrrolo[2,3-d]pyrimidines
- Direct Parent
- Pyrrolo[2,3-d]pyrimidines
- Alternative Parents
- Pyrimidines and pyrimidine derivatives / Pyrroles / Pyrazoles / Heteroaromatic compounds / Nitriles / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Pyrrolo[2,3-d]pyrimidine / Pyrimidine / Heteroaromatic compound / Pyrrole / Pyrazole / Azole / Azacycle / Nitrile / Carbonitrile / Organic nitrogen compound
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- pyrazoles, nitrile, pyrrolopyrimidine (CHEBI:66919)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Ubiquitin protein ligase binding
- Specific Function
- Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor.
- Gene Name
- JAK1
- Uniprot ID
- P23458
- Uniprot Name
- Tyrosine-protein kinase JAK1
- Molecular Weight
- 133275.995 Da
References
- Cervantes F, Martinez-Trillos A: Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013 May;14(7):873-84. doi: 10.1517/14656566.2013.783019. Epub 2013 Mar 21. [PubMed:23514013]
- Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. [PubMed:23061804]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Sh2 domain binding
- Specific Function
- Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptiv...
- Gene Name
- JAK2
- Uniprot ID
- O60674
- Uniprot Name
- Tyrosine-protein kinase JAK2
- Molecular Weight
- 130672.475 Da
References
- Cervantes F, Martinez-Trillos A: Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013 May;14(7):873-84. doi: 10.1517/14656566.2013.783019. Epub 2013 Mar 21. [PubMed:23514013]
- Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. [PubMed:23061804]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. [PubMed:23061804]
Drug created on May 13, 2013 12:21 / Updated on June 21, 2018 22:13